EMD Serono, a subsidiary of Merck, has created a new immuno-oncology platform, which combines research, early development and biomarker strategies to advance investigational immunotherapies to fight cancer.
Merck Serono Global Research and Early Development head Bernhard Kirschbaum said the platform recognizes the complexity of cancer, which requires diverse approaches to enable alternative therapeutic interventions.
"In order to spur research and early development in this specialized area, we have created an innovative environment where researchers and clinicians work side-by-side to advance potential new cancer immunotherapies," Kirschbaum added.
Consisting of three innovation clusters, including Therapeutic cancer vaccines, Cancer stem cells and Immunotolerance, the overall new immuno-oncology platform will focus on discovery research and the advancement of molecules into the clinic.
The current immuno-oncology portfolio includes therapeutic candidates in early clinical development and a series of pre-clinical molecules.
EMD Serono has assembled an in-house team of researchers and clinicians to ensure a broad immuno-oncology research and early development platform.
The in-house team will collaborate with academia, research and industry organizations to complement internal capabilities and focus resources and technologies to build a portfolio of investigational immunotherapies.
Merck Serono Global Research and Early Development Immuno-Oncology head Helen Sabzevari said, "Our goal is to develop leading immunotherapies that work in combination with other therapeutic modalities, understanding that attacking multiple cancer targets simultaneously increases the possibility of therapeutic success."